{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:12:19Z","timestamp":1791994339306,"version":"4.4.0"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.blre.2025.101353","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T11:48:15Z","timestamp":1763639295000},"page":"101353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Long-term durability of rAAV gene therapy in hemophilia: Factor expression, clinical outcomes and underlying molecular mechanisms"],"prefix":"10.1016","volume":"75","author":[{"given":"Yesim","family":"Dargaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela G.","family":"Yamaguti-Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9ssica O.","family":"Frade-Guanaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Leuci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margareth C.","family":"Ozelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2025.101353_bb0005","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0140-6736(24)02139-1","article-title":"Haemophilia","volume":"405","author":"Chowdary","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2025.101353_bb0010","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1182\/blood-2018-08-872291","article-title":"New therapies for hemophilia","volume":"133","author":"Weyand","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101353_bb0015","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0140-6736(20)32722-7","article-title":"The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing","volume":"397","author":"Mancuso","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2025.101353_bb0020","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1056\/NEJMe2024545","article-title":"Treatment of hemophilia \u2014 more amazing Progress","volume":"383","author":"Mannucci","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101353_bb0025","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1080\/14656566.2023.2196012","article-title":"Current factor IX replacement options for hemophilia B and the challenges ahead","volume":"24","author":"Franchini","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.blre.2025.101353_bb0030","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40268-024-00481-7","article-title":"Damoctocog alfa Pegol, a PEGylated B-domain deleted recombinant extended half-life factor VIII for the treatment of hemophilia a: a product review","volume":"24","author":"Reding","year":"2024","journal-title":"Drugs R D"},{"key":"10.1016\/j.blre.2025.101353_bb0035","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"Von Drygalski","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101353_bb0040","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2023.284498","article-title":"Efanesoctocog alfa: the renaissance of factor VIII replacement therapy","author":"Dargaud","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101353_bb0045","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood.2019000658","article-title":"Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia a","volume":"134","author":"van den Berg","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101353_bb0050","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/hae.12229","article-title":"Prevalent inhibitors in haemophilia B subjects enrolled in the universal data collection database","volume":"20","author":"Puetz","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101353_bb0055","first-page":"15","article-title":"Future needs for continuing innovation in hemophilia: Improving outcomes for individuals of all severities, including women and those in resource-constrained regions","author":"Blatn\u00fd","year":"2024","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2025.101353_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101353_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100179","article-title":"Antithrombin-lowering in hemophilia: a closer look at fitusiran","volume":"7","author":"Young","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101353_bb0070","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.3390\/jcm14092961","article-title":"Concizumab, a non-replacement therapy for persons with hemophilia with inhibitors","volume":"14","author":"Castaman","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.blre.2025.101353_bb0075","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/bjh.18495","article-title":"Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: phase II study results","volume":"200","author":"Mahlangu","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101353_bb0080","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13023-022-02313-w","article-title":"Haemophilia gene therapy: experiences and lessons from treated patients","volume":"17","author":"Hermans","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.blre.2025.101353_bb0085","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/hematology.2022000388","article-title":"Gene therapy for hemophilia","volume":"2022","author":"Nathwani","year":"2022","journal-title":"Hematology"},{"key":"10.1016\/j.blre.2025.101353_bb0090","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-med-043021-033013","article-title":"Adeno-associated virus gene therapy for hemophilia","volume":"74","author":"Samelson-Jones","year":"2023","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.blre.2025.101353_bb0095","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1182\/bloodadvances.2024014111","article-title":"Adeno-associated virus\u2013based gene therapy for hemophilia a and B: a systematic review and meta-analysis","volume":"8","author":"Deshpande","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101353_bb0100","first-page":"13","article-title":"Managing the challenges of paying for gene therapy: strategies for market action and policy reform in the United States","author":"Phares","year":"2024","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.blre.2025.101353_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2024.109064","article-title":"Liver health in hemophilia in the era of gene therapy","volume":"240","author":"Dargaud","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2025.101353_bb0110","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1182\/blood.2019002867","article-title":"Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum","volume":"135","author":"Poothong","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101353_bb0115","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.omtm.2020.07.005","article-title":"Induction of ER stress by an AAV5 BDD FVIII construct is dependent on the strength of the hepatic-specific promoter","volume":"18","author":"Fong","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.blre.2025.101353_bb0120","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.ymthe.2022.03.004","article-title":"Durability of transgene expression after rAAV gene therapy","volume":"30","author":"Muhuri","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2025.101353_bb0125","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/j.ymthe.2025.03.041","article-title":"The deLIVERed promises of gene therapy: past, present, and future of liver-directed gene therapy","volume":"33","author":"Puzzo","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2025.101353_bb0130","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1053\/j.gastro.2009.05.044","article-title":"Stem Cells and Liver Regeneration","volume":"137","author":"Duncan","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.blre.2025.101353_bb0135","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jtha.2023.12.005","article-title":"Deciphering conundrums of adeno-associated virus liver-directed gene therapy: focus on hemophilia","volume":"22","author":"Pierce","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101353_bb0140","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A long-term study of AAV gene therapy in dogs with hemophilia a identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.blre.2025.101353_bb0145","first-page":"4324","article-title":"Gene therapy for hemophilia","volume":"20","author":"Rogers","year":"2015","journal-title":"Front Biosci"},{"key":"10.1016\/j.blre.2025.101353_bb0150","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1182\/blood-2005-10-4035","article-title":"Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver","volume":"107","author":"Nathwani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101353_bb0155","article-title":"Diploid hepatocytes drive physiological liver renewal in adult humans","volume":"13","author":"Heinke","year":"2022","journal-title":"Cell Syst"},{"key":"10.1016\/j.blre.2025.101353_bb0160","doi-asserted-by":"crossref","first-page":"9409","DOI":"10.3390\/ijms23169409","article-title":"Implications of polyploidy and ploidy alterations in hepatocytes in liver injuries and cancers","volume":"23","author":"Matsumoto","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2025.101353_bb0165","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101353_bb0170","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune responses to viral gene therapy vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2025.101353_bb0175","first-page":"11","article-title":"Human immune responses to adeno-associated virus (AAV) vectors","author":"Ronzitti","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2025.101353_bb0180","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1172\/JCI37607","article-title":"The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice","volume":"119","author":"Zhu","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2025.101353_bb0185","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1172\/JCI68205","article-title":"CpG-depleted adeno-associated virus vectors evade immune detection","volume":"123","author":"Faust","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.blre.2025.101353_bb0190","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/j.ymthe.2025.03.043","article-title":"Gene therapy for hemophilia \u2013 from basic science to first approvals of \u201cone-and-done\u201d therapies","volume":"33","author":"Herzog","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2025.101353_bb0195","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2025.101353_bb0200","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8+ T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2025.101353_bb0205","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5\u2013factor VIII gene transfer in severe hemophilia a","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101353_bb0210","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene Roxaparvovec gene therapy for hemophilia a","volume":"386","author":"Ozelo","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101353_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102615","article-title":"Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia a in the phase 3 GENEr8-1 trial","volume":"8","author":"Leavitt","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101353_bb0220","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1016\/j.jtha.2024.04.001","article-title":"Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia a","volume":"22","author":"Madan","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101353_bb0225","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of Valoctocogene Roxaparvovec therapy for hemophilia a","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101353_bb0230","first-page":"21","article-title":"Efficacy and safety of Valoctocogene Roxaparvovec for severe hemophilia a 5 years after gene transfer in GENEr8-1","volume":"31","author":"Mahlangu","year":"2025","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101353_bb0235","article-title":"Variability in FVIII transgene expression among patients treated with Valoctocogene Roxaparvovec (poster abstracts ISTH 2025)","volume":"9","author":"Ciavarella","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101353_bb0240","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1007\/s12325-024-02834-9","article-title":"Comparative effectiveness of Valoctocogene Roxaparvovec and prophylactic factor VIII replacement in severe hemophilia a","volume":"41","author":"Oldenburg","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.blre.2025.101353_bb0245","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/17474086.2025.2467861","article-title":"A plain language summary on indirectly comparing bleeding after valoctocogene roxaparvovec gene therapy to bleeding with emicizumab prophylaxis","volume":"18","author":"Astermark","year":"2025","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.blre.2025.101353_bb0250","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/hae.14818","article-title":"Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia a: comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis","volume":"29","author":"Astermark","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101353_bb0255","doi-asserted-by":"crossref","DOI":"10.1007\/s12325-025-03368-4","article-title":"Estimated Long-term durability of Valoctocogene Roxaparvovec treatment in male patients with severe hemophilia a: an extrapolation of clinical data","author":"Santos","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.blre.2025.101353_bb0260","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1089\/hum.2018.137","article-title":"Preclinical development of a hematopoietic stem and progenitor cell bioengineered factor VIII lentiviral vector gene therapy for hemophilia a","volume":"29","author":"Doering","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.blre.2025.101353_bb0265","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1056\/NEJMoa2410597","article-title":"Lentiviral gene therapy with CD34+ hematopoietic cells for hemophilia a","volume":"392","author":"Srivastava","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101353_bb0270","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear factor VIII expression after AAV gene transfer for hemophilia a","volume":"385","author":"George","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101353_bb0275","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.2022018971","article-title":"Giroctocogene fitelparvovec gene therapy for severe hemophilia a: 104-week analysis of the phase 1\/2 Alta study","volume":"143","author":"Leavitt","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101353_bb0280","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1182\/blood-2023-179422","article-title":"Four-year follow-up of the Alta study, a phase 1\/2 study of Giroctocogene Fitelparvovec (PF-07055480\/SB-525) gene therapy in adults with severe hemophilia \u0391","volume":"142","author":"Harrington","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101353_bb0285","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1182\/blood-2024-208486","article-title":"Efficacy and safety of Giroctocogene Fitelparvovec in adults with moderately severe to severe hemophilia \u0391: primary analysis results from the phase 3 \u0391FFINE gene therapy trial","volume":"144","author":"Leavitt","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101353_bb0290","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/hae.15121","article-title":"A phase 1\/2 safety and efficacy study of TAK-754 gene therapy: the challenge of achieving durable factor VIII expression in haemophilia a clinical trials","volume":"31","author":"Chapin","year":"2025","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101353_bb0295","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1182\/blood-2002-10-3296","article-title":"AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B","volume":"101","author":"Manno","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101353_bb0300","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-Associated Virus Vector\u2013Mediated Gene Transfer in Hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101353_bb0305","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1056\/NEJMoa2414783","article-title":"Sustained clinical benefit of AAV gene therapy in severe hemophilia B","volume":"392","author":"Reiss","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101353_bb0310","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-139225","article-title":"AMT-060 gene therapy in adults with severe or moderate-severe hemophilia B confirm stable FIX expression and durable reductions in bleeding and factor IX consumption for up to 5 years","volume":"136","author":"Leebeek","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101353_bb0315","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ymthe.2017.12.007","article-title":"Hyperactive factor IX Padua: a game-changer for hemophilia gene therapy","volume":"26","author":"VandenDriessche","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2025.101353_bb0320","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5\u2013human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101353_bb0325","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"Von Drygalski","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101353_bb0330","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1182\/bloodadvances.2022008886","article-title":"Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy","volume":"7","author":"von Drygalski","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2025.101353_bb0335","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/hae.14977","article-title":"Effect of etranacogene dezaparvovec on quality of life for severe and moderately severe haemophilia B participants: results from the phase III HOPE-B trial 2 years after gene therapy","volume":"30","author":"Itzler","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2025.101353_bb0340","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with Etranacogene Dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101353_bb0345","article-title":"OC 69.4 Etranacogenedezaparvovec in haemophilia B: a 48-month post hoc responder analysis of HOPE-B (025 Oral communications abstracts). Res Pract","volume":"9","author":"Leebeek","year":"2025","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101353_bb0350","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/S2352-3026(24)00006-1","article-title":"Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial","volume":"11","author":"Coppens","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2025.101353_bb0355","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/03007995.2022.2133492","article-title":"Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B","volume":"39","author":"Shah","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.blre.2025.101353_bb0360","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a High-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101353_bb0365","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2302982","article-title":"Gene therapy with Fidanacogene Elaparvovec in adults with hemophilia B","volume":"391","author":"Cuker","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101353_bb0370","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa2307159","article-title":"Fidanacogene Elaparvovec for hemophilia B \u2014 a multiyear follow-up study","volume":"392","author":"Rasko","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101353_bb0375","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s40262-025-01535-y","article-title":"Population modeling of factor IX activity following Administration of Fidanacogene Elaparvovec Gene Therapy in participants with hemophilia B","volume":"64","author":"Wojciechowski","year":"2025","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.blre.2025.101353_bb0380","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101353_bb0385","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.ymthe.2025.05.014","article-title":"China\u2019s first approved gene therapy for hemophilia B: a new era for global AAV-based treatments","volume":"33","author":"Wei","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2025.101353_bb0390","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1016\/S2352-3026(22)00113-2","article-title":"Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-Centre, single-arm, phase 1, pilot trial","volume":"9","author":"Xue","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2025.101353_bb0395","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101353_bb0400","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1056\/NEJMoa2119913","article-title":"Phase 1\u20132 trial of AAVS3 gene therapy in patients with hemophilia B","volume":"387","author":"Chowdary","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2025.101353_bb0405","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/j.ymthe.2024.06.009","article-title":"AAV vectors for long-term gene therapy of hemophilia B: are we there yet?","volume":"32","author":"Srivastava","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2025.101353_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102673","article-title":"Adeno-associated virus-based gene therapy for hemophilia\u2013addressing the gaps","volume":"9","author":"Miesbach","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101353_bb0415","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.omtn.2023.03.008","article-title":"In vivo genome editing for hemophilia B therapy by the combination of rebalancing and therapeutic gene knockin using a viral and non-viral vector","volume":"32","author":"Lee","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.blre.2025.101353_bb0420","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.ymthe.2025.04.023","article-title":"Clinical perspective: advancing hemophilia treatment through gene therapy approaches","volume":"33","author":"Thornburg","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.blre.2025.101353_bb0425","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.omtm.2020.06.025","article-title":"CRISPR-Cas9-mediated in vivo gene integration at the albumin locus recovers hemostasis in neonatal and adult hemophilia B mice","volume":"18","author":"Wang","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.blre.2025.101353_bb0430","first-page":"8","article-title":"In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia a and B therapy","author":"Han","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.blre.2025.101353_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.102710","article-title":"Development of a novel gene editing lexicon for hemophilia: methodology and results","volume":"9","author":"Kessler","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101353_bb0440","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood-2023-182468","article-title":"Development of an ex vivo precision gene engineered B cell medicine that produces active and sustained levels of FIX for the treatment of hemophilia B","volume":"142","author":"Liu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101353_bb0445","series-title":"A Precision Gene Engineered B Cell Medicine Producing Sustained Levels of Active Factor IX for Hemophilia B Therapy","author":"Liu","year":"2025"},{"key":"10.1016\/j.blre.2025.101353_bb0450","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1111\/jth.13520","article-title":"Baboon envelope pseudotyped lentiviral vectors efficiently transduce human B cells and allow active factor IX B cell secretion in vivo in NOD\/SCID\u03b3c-\/- mice","volume":"14","author":"Levy","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2025.101353_bb0455","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1182\/bloodadvances.2024015291","article-title":"Completion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years","volume":"9","author":"von Drygalski","year":"2025","journal-title":"Blood Adv"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T04:16:07Z","timestamp":1772511367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25000980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":91,"alternative-id":["S0268960X25000980"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101353","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term durability of rAAV gene therapy in hemophilia: Factor expression, clinical outcomes and underlying molecular mechanisms","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101353","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101353"}}